

**Amendments to the Specification:**

Please add the following new paragraphs after the brief description of Fig. 10 in the Brief Description of the Drawings Section of the Specification:

FIG. 11 shows the inhibition of DU-145 human prostate cancer growth by the AT<sub>4</sub> receptor antagonist, NORLEUAL.

FIG. 12 is color plate showing the effect of the AT<sub>4</sub> receptor antagonist, NORLEUAL, on the net deposition of extracellular matrix protein by human dermal fibroblasts and C6 glioma cells.

FIG.13 is a color plate showing the effect of the AT<sub>4</sub> receptor antagonist, NORLEUAL, on the net deposition of extracellular matrix protein by human umbilical vein endothelial cells and +SA-WAZ-2T murine breast cancer cells.

FIG. 14 is a color plate showing the inhibitory effect of the AT<sub>4</sub> receptor antagonist, NORLEUAL, on the growth of +SA-WAZ-2T murine primary tumors in mice.

FIG. 15 is a color plate showing the inhibition of tumor angiogenesis in mice following application of the AT<sub>4</sub> receptor antagonist, NORLEUAL.